Story perspectives

FDA Extends Review After Panel Rejects AstraZeneca Pill

5/28/2026

Summary

FDA Extends Review

The U.S. Food and Drug Administration extended the decision deadline for AstraZeneca’s experimental breast-cancer pill camizestrant to review additional data.
In April, an FDA advisory panel voted against camizestrant with a CDK4/6 inhibitor, citing trial-design flaws and deeming the benefit evidence inconclusive.
The European Medicines Agency recommended approval and will market camizestrant as Etcamah in Europe, though SERENA-6 showed a 56% reduction in progression or death, leaving U.S. experts skeptical.

Summary

Camizestrant Expands Market

Camizestrant has been approved in the United Arab Emirates and Saudi Arabia, expanding market.
In the United States, it competes with Orserdu (elacestrant) and Inluriyo (imlunestrant) for therapy.
Oncology head Susan Galbraith said SERENA-6’s ctDNA-based ESR1 monitoring could set camizestrant apart.
SERENA-4 trial results, due later this year, are viewed as pivotal for a first-line indication.
AstraZeneca is also testing camizestrant after surgery in earlier-stage breast cancer to broaden use.

1 of 2

FDA Extends Review

The U.S. Food and Drug Administration extended the decision deadline for AstraZeneca’s experimental breast-cancer pill camizestrant to review additional data.
In April, an FDA advisory panel voted against camizestrant with a CDK4/6 inhibitor, citing trial-design flaws and deeming the benefit evidence inconclusive.
The European Medicines Agency recommended approval and will market camizestrant as Etcamah in Europe, though SERENA-6 showed a 56% reduction in progression or death, leaving U.S. experts skeptical.

1 / 2